Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 2Phase 2 2Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 12Central Nervous System Neoplasms 11Brain Neoplasms 9Astrocytoma 8Glioma 6Oligodendroglioma 4Gliosarcoma 3Neoplasms 2Medulloblastoma 2Leukemia, Myeloid, Acute 2Spinal Cord Neoplasms 1Optic Nerve Glioma 1Neoplasms, Plasma Cell 1Neoplasm Recurrence, Local 1Multiple Myeloma 1Cognition Disorders 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Lomustine × Clear all
NCT07100730 2026-04-16

IPAX BrIGHT

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
50 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neoplasms, Central Nervous System Neoplasms

NCT00761280 2014-11-14

SAPPHIRE

Isarna Therapeutics GmbH

Phase 3 Terminated
27 enrolled 28 charts
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡